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Abstract: Metabolic syndrome (MetS) is prevalent not only among the overweight and obese but also
normal weight individuals, and the phenotype is referred to as a metabolically unhealthy phenotype
(MUHP). Besides normal weight individuals, overweight/obese individuals are also protected from
MetS, and the phenotype is known as a metabolically healthy phenotype (MHP). Epidemiological
studies indicate that coffee and micronutrients such as plasma folate or vitamin B12 (vit. B12)
are inversely associated with MetS. However, correlations among coffee consumption metabolic
phenotypes, plasma folate, and vit. B12 remain unknown. Our objective was to investigate the
correlation between coffee consumption, metabolic phenotypes, plasma folate, and vit. B12 as well as
to understand associations between plasma folate, vit. B12, and metabolic phenotypes. Associations
among coffee consumption metabolic phenotypes, plasma folate, and vit. B12 were assessed in a
cross-sectional study of 2201 participants, 18 years or older, from 2003–2004 and 2005–2006 National
Health and Nutrition Examination Surveys (NHANES). MUHP was classified as having > three
metabolic abnormalities. Coffee consumption was not associated with metabolic phenotypes, but
negatively correlated with several metabolic variables, including BMI (p < 0.001). Plasma folate
was positively associated with MUHP (p < 0.004), while vit. B12 was inversely associated with
MUHP (p < 0.035). Our results suggest the potential protective impact of coffee on individual
components of MetS and indicate a positive correlation between coffee consumption and MUHP
among overweight individuals. Identifying possible dietary factors may provide practical and
low-cost dietary intervention targets, specifically for early intervention. Larger and randomized
intervention studies and prospective longitudinal studies are required to further evaluate these
associations.
Keywords: coffee; metabolic healthy obesity; metabolically healthy phenotype; metabolically
unhealthy phenotypes
1. Introduction
Obesity is prevalent in about 36.5% of the U.S. adult population (ages 20–74 years) [1]
and associated with a high risk of metabolic syndrome (MetS), cardiovascular diseases
(CVD), type 2 diabetes (T2D), certain cancers, and other causes of preventable deaths [2].
MetS, as defined by International Diabetes Federation and Karelis et al., includes an
index of insulin resistance such as homeostatic model assessment of insulin resistance
(HOMA-IR), hyperlipidemia risk factors such as low levels of high-density lipoproteins
(HDL), high plasma levels of triglycerides or low-density lipoprotein (LDL), markers
of inflammation such as high-sensitivity C-reactive protein (hsCRP), increased levels of
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plasma homocysteine (Hcy), abnormal plasma glucose, abnormal blood pressure as well
as high levels of visceral and/or liver fat [3,4]. In the past decade a sub-set of the obese
population have been identified who are “protected” from MetS, and the phenotype is
classified as “metabolically healthy obesity (MHO)” [5]. Initially defined by Sims in 2001 [6],
MHO is also referred to as metabolically healthy phenotype (MHP) and is identified by
an absence of MetS [3,4,7,8]. There is no general consensus regarding the definition of
MHP. Therefore, based on the definition of obesity, metabolic markers, and their cut-off
point criteria, the prevalence of MHP varies significantly among the adult U.S. population
and ranges from 3.3 to 57.5% [3,9]. A recent study by Al-Khalidi et al. and Winter et al.
defined MHP as obese individuals with zero metabolic abnormality [9,10]. Some studies
have also included deficiencies of plasma vitamin D and ferritin levels as part of MetS
classification, and both plasma vitamin D and ferritin are found be inversely associated
with MHP [9,11,12]. It has been suggested that MHP may be transient, with genetics
and lifestyle factors substantially contributing towards transitioning from MHP to MUHP.
However, protective factors that promote MHP are not well studied [13]. One recent
prospective study indicated that among several dietary factors, higher coffee intake was
associated with a reduced risk of developing MUHP among normal weight, overweight,
and obese individuals [14].
For more than two decades, coffee consumption has risen worldwide and is the most
consumed beverage in the United States, even more than water [15,16]. Habitual coffee
consumption is found to be inversely associated with total and cause-specific mortality
as well as several chronic diseases [17–23]. Besides caffeine, brewed coffee contains sev-
eral bioactive compounds including polyphenols and diterpene alcohols such as cafestol
and kahweol, which are associated with lower incidences of metabolic syndrome and
CVD risk factors including high blood pressure, plasma cholesterol, and homocysteine
(Hcy) [15,17,24,25]. Epidemiological studies indicate that higher coffee consumption re-
duced the genetic associations with body mass index (BMI) and obesity risk and type 2
diabetes [26–28]. Gene–diet interaction analysis in three US prospective studies indicated
that the higher consumption of coffee was associated with reduced obesity risk among
individuals who were genetically predisposed to obesity as measured by 77 BMI-associated
single nucleotide polymorphisms (SNPs) [26]. Similarly, in a weight loss intervention study,
the genetic risk factors consisting of eight habitual coffee consumption-associated SNPs
related to coffee and glucose metabolism was reduced by habitual coffee consumption [27].
In contrast, a pooled analysis of four Korean prospective studies with 71,527 participants
indicated that consumption of more than three cups of coffee/day significantly reduced
the risk of T2D but was not associated with five SNPs associated with T2D [28]. Several
studies identified a positive association between coffee intake and reduced incidence of
MetS, while other studies did not [29–33]. Inconsistencies in the correlations between coffee
consumption and MetS could stem from type (caffeinated vs. decaffeinated) and variety
of coffee, amount of coffee (cups/day), other ingredients such as milk, cream, and sugar
added to coffee or confounding factors such as smoking [18,34]. Cytochrome (CYP) P450
1A2 is the enzyme involved in breakdown or metabolizing caffeine. Studies indicate that
interindividual variations in CYP P450 1A2 may partly be responsible for the inconsistent
associations between habitual coffee consumption and disease risks [35–37].
Mechanisms by which coffee may reduce MetS are not clearly understood but may
be associated in part with the ability of chlorogenic acids (CGAs) and other bioactive
components in coffee, rather than caffeine, to reduce intestinal glucose absorption or
improve insulin sensitivity or the association of coffee consumption with improved levels
of leptin and ghrelin, which regulate appetite, satiety, and energy metabolism [38–47].
Elevated plasma levels of hyperhomocysteinemia (Hcy) have been suggested to be
both a cause and a consequence of the MetS and is associated with smoking habits, al-
cohol and caffeine abuse, or a diet low in fruits and vegetables. However, association of
hyperhomocysteinemia with overall coffee intake is inconsistent. Study by Miranda et al.
indicated that coffee intake of 1–3 cups/day and its polyphenols were inversely associated
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with hyperhomocysteinemia [24], while other studies, including those by Grubben et al.,
demonstrated that consumption of more than two cups of coffee/day was associated with
increased levels of plasma Hcy [48–50]. Hcy is a sulfur-containing amino acid whose
plasma levels in humans are correlated with not only deficiencies, but also suboptimal
nutritional status of vitamin B6, B12, and folate, which serve as cofactors and methyl
donors in Hcy metabolism [50,51]. Coffee and chlorogenic acid consumption significantly
increased plasma Hcy levels, while independent studies indicate negative correlations
between coffee consumption and plasma folate and vit. B12 [52–57].
The primary goal of our study was to determine the association between coffee
consumption and MHP (defined by <3 cardiometabolic abnormalities) and MUHP (defined
by >3 cardiometabolic abnormalities) using data from the Continuous National Health and
Nutritional Examination Survey (NHANES; 2003–2004 and 2005–2006). Our secondary
objective was to understand the correlation between coffee intake and modulators of
Hcy metabolism, specifically plasma folate and vit. B12, and the modulators’ possible
associations with metabolic phenotypes.
2. Materials and Methods
2.1. Study Population
NHANES is a population-based cross-sectional survey, which examines the health and
nutritional status of children and adults in the United States. A random sampling method
is used to select participants. The survey involves a home interview and a medical exam.
The home interview comprises questions related to demographics, socioeconomic status
as well as dietary and health information. Medical exams include dental and physical
exams, physiological measurements, and laboratory tests. Public use datasets for the
ongoing NHANES are released by the National Center for Health Statistics (NCHS) of
Center for Disease Control and Prevention (CDC) in two-year cycles. The NCHS ethics
committee approved NHANES study protocol. Details for the NHANES study design are
published elsewhere [58]. Data for this project were obtained from Continuous NHANES
Data, Questionnaires, and Related Documentation for the years 2003–2004 and 2005–2006.
The time frame was chosen since NHANES stopped collecting data on vit. B12 and folate
after 2006.
Participants 18 years and older were included in the study. NHANES 2003–2004
and 2005–2006 included a total of 6708 participants (Figure 1). Since the objective was
to understand the correlation between coffee intake and metabolic phenotypes (MHP
and MUHP) and not the end stage diseases, participants were excluded based on their
cardiovascular diseases status such as congestive heart failure, coronary heart disease,
angina, heat attack or stroke (n = 429), and diabetes (n = 394). In addition, those who
lacked smoking and drinking history (n = 2172), were pregnant (n = 278), missing coffee
consumption data (n = 1014), and missing or zero sample weights (n = 220) were also
excluded from the analysis. Final study sample size was n = 2201 participants (1054 males
and 1147 females).
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Figure 1. Study participant selection criteria, NHANES 2003 to 2006. 
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2.2. Data Collection
Twelve-month food frequency questionnaires and 24-h dietary recalls collected from
NHANES 2003–2004 and 2005–2006 were used to obtain caffeine and coffee consumption
data [58]. Caffeine consumption included all sources of caffeine drinks, such as tea, soft
drinks, energy drinks, etc. Participants consuming caffeinated coffee were included, while
participants consuming decaffeinated coffee were not considered in our study. All types of
coffee brewing methods were included in the dataset such as coffee brewed at home, cafes
or restaurants, black coffee or those with cream or sugar, filter coffee, expresso, cold brew,
etc. The frequency of coffee consumption was reported as <1 cup/month, 1–3 cups/month,
1 cup/week, 2–4 cups/week, 5–6 cups/week, 1 cup/day, 2–3 cups/day, 4–5 cups/day,
or ≥6 cups/day, based on the 24-h dietary recall. It was further categorized as none or
≤1 cup/week, 2–6 cups/week, 1 cup/day, and ≥2 cups/day (1 cup = 8 oz) for analysis.
2.3. Classification of MetS, Metabolically Healthy, and Unhealthy Phenotypes
Based on American Heart Association/National Heart, Lung and Blood Institute
(AHA/NHLB) criteria for MetS diagnosis, an individual should have a minimum of three
out of five metabolic ab orm lities that includes: (1) waist circumference ≥90 cm for men
and ≥80 cm for women; (2) triglyceride ≥ 150 mg/dL or medication for hyperlipidemia;
(3) HDL cholesterol < 40 mg/dL for men and <50 mg/dL fo women; (4) blood pressure
≥ 130/85 mmHg or medicat on fo hypertension; (5) fasting blood glucos ≥ 100 g/dL
or taking gluc se lowering medication [59]. There is currently no consensus about the
definition of MHP and MUHP, and it varies based on he criteria as well as cutoff values,
hereby influ ncing the pr valence and outcomes [9,10,60]. Overall, MHP is define as
obese individu ls with normal fasting glucose, i sulin sens tivity, b ood lipid profil ,
blood press re, a d absence of MetS [61,62].
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MHP in our study was based on the definition of MetS and defined as those indi-
viduals with less than three metabolic abnormalities, and MUHP was classified as those
participants with more than or equal to three metabolic abnormalities, independent of their
BMI status. We also evaluated the effects of smoking, physical activity, and alcohol on
metabolic phenotypes, since these health behaviors are known risk factors for metabolic
syndrome [63,64].
2.4. Plasma Folate and Vitamin B12
The NHANES questionnaire and phlebotomy exam files are linked to a laboratory data
file by using the unique survey participant identifier SEQN. The Phlebotomy Examination
file contains information on duration of fasting, time of blood draw, and the conditions
that would exclude the blood draw. Plasma or serum are analyzed at the Division of
Environmental Health Laboratory Sciences, National Center for Environmental Health,
and Centers for Disease Control and Prevention (https://wwwn.cdc.gov/Nchs/Nhanes/
2005-2006/B12_D.htm (accessed on 20 September 2020)).
Both serum folate and vitamin B12 were measured by using the Bio-Rad Laboratories
“Quantaphase II Folate/Vitamin B12” radio-assay kit. Specimen collection and process-
ing instructions are specified on the NHANES website (https://wwwn.cdc.gov/Nchs/
Nhanes/2005-2006/B12_D.htm (accessed on 15 September 2020)). Plasma folate quar-
tiles were data driven and were categorized as <8.3, 8.3–<11.5, 11.5–<16.1, ≥16.1 ng/mL.
Plasma vit. B12 was categorized based on quartiles <359.0, 359.0–<470.5, 470.5–<634.5, and
≥634.5 pg/mL, as published [65].
2.5. Covariates
Additional covariates included in the analysis were demographic variables such as
age group (categorized as 20–34, 35–49, 50–64, 65–79, and ≥80 years), sex (male vs. female),
race/ethnicity (categorized as non-Hispanic White, Mexican American or Hispanic, Non-
Hispanic Black, and other). Health behavior variables included smoking status (categorized
as never, former, or current smoker), alcohol drinker (categorized as never, former or current
drinker, where current drinker was further categorized as <1 drink/day, 1–2 drinks/day,
and >2 drinks/day), and physical activity (metabolic equivalent of task, MET, categorized
as <5, 5–19.9, 20–49.9, and ≥50 h/week). MET is a unit to estimate energy expenditure
above resting metabolic rate during all levels of physical activity (light, moderate, heavy)
including walking [66]. Other metabolic characteristics include body mass index (BMI,
categorized as normal, overweight, and obese), triglycerides, low-density lipoprotein
(LDL-c), high-density lipoproteins (HDL-c), C-reactive protein (CRP), and homeostasis
model assessment-estimated insulin resistance (HOMA-IR). BMI was calculated from the
physical examination survey that recorded anthropometric data for height, weight, and
waist circumference. Smoking history, alcohol consumption and physical activity data
were collected from the lifestyle questionnaire. Details for each variable measurement is
published on the NHANES website [67].
2.6. Statistical Analysis
The survey data were summarized by descriptive statistics, followed by one-way
analysis of variance (ANOVA) for continuous variables and Rao–Scott chi-square tests
for categorical variables to assess associations between metabolic phenotypes and other
factors. The analysis accounted for the stratified, multistage probability cluster sampling
design of NHANES. NHANES provides sampling weights to be used in analyses that
account for oversampling of certain subgroups [67]. Coffee consumption was the primary
independent variable, and metabolic phenotypes were the main outcome variable. We also
assessed the relationships between B12 and folate with the outcome, and adjusted them
in the main analysis (between coffee and metabolic phenotypes) and stratified by BMI
status. Associations between micronutrients and coffee consumption were also assessed.
Variables with p < 0.1 in the bivariate analysis were included in the multivariable logistic
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regression analysis and backward selection method was performed to determine final
significant variables keeping the primary independent variables of interest in the model.
Logistic analyses were performed to model the association between metabolic phenotypes
(outcome) and coffee intake. Odds ratios (ORs) and their 95% confidence intervals (CIs)
were calculated. All analyses accounted for NHANES’ complex multistage sampling
design, and p < 0.05 was considered statistically significant. Statistical analyses were
conducted using SAS software, version 9.4 (SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. Baseline Characteristics of Participants
General characteristics of coffee drinkers for NHANES 2003–2006 has been described
by Loftfield et al. [58]. In our study, among the 2201 participants analyzed in the 2003–2006
NHANES data, 1708 (77.6%) of the individuals demonstrated MHP, while 493 (22.4%)
individuals demonstrated an unhealthy phenotype (Table 1). Younger age, sex (female),
and Mexican American and non-Hispanic Black were significantly associated with a healthy
phenotype (Table 1, all p-values < 0.001). As expected, smoking status and number of
alcoholic drinks consumed were negatively associated with MHP, while physical activity
was positively associated with MHP (Table 1, p = 0.002, p < 0.001 and p = 0.003, respectively).
All five MetS components—waist circumference, blood pressure, glucose, HDL-c, and
triglyceride—were negatively correlated with MHP (Table 1, all p-values < 0.001). Similarly,
HOMA-IR components, BMI, and total cholesterol were negatively correlated with MHP
(Table 1, all p-values < 0.001). Our analysis indicated that LDL-c and CRP were not
associated with metabolic phenotypes (Table 1).










Age Group, years (n, %) <0.001
20–34 524 (30.9%) 36 (8.8%)
35–49 507 (36.0%) 103 (28.6%)
50–64 341 (21.7%) 166 (37.6%)
65–79 213 (8.2%) 151 (21.7%)
≥80 123 (3.1%) 37 (3.3%)
Sex (n, %) <0.001
Male 790 (43.1%) 264 (53.8%)
Female 918 (56.9%) 229 (46.1%)
Race/Ethnicity (n, %) <0.001
Non-Hispanic White 924 (73.0%) 313 (83.0%)
Mexican American or Hispanic 353 (10.5%) 90 (5.1%)
Non-Hispanic Black 353 (11.0%) 73 (7.1%)
Other 78 (5.4%) 17 (4.8%)
Health Behaviors
Smoker (n, %) 0.002
Never 917 (52.5%) 232 (47.5%)
Former 409 (22.8%) 169 (32.4%)
Current 382 (24.8%) 92 (20.1%)










Alcohol Drinker (n, %) <0.001
Never 209 (11.3%) 70 (15.6%)
Former 252 (14.1%) 92 (21.6%)
Current: <1 drink/day 773 (56.5%) 190 (48.8%)
1–2 drinks/day 171 (11.8%) 28 (6.4%)
>2 drinks/day 81 (6.3%) 28 (7.6%)
Physical Activity
MET hour/week (n, %) 0.003
<5.0 259 (21.4%) 79 (29.6%)
5.0–19.9 407 (36.3%) 121 (40.5%)
20.0–49.9 290 (26.9%) 62 (21.9%)
≥50.0 170 (15.3%) 25 (8.0%)
MetS Components
Waist circumference, cm (Mean ± SE) 92.69 ± 0.36 111.46 ± 0.75 <0.001
Waist circumference, cm (n, %) <0.001
≥102 373 (21.3%) 378 (81.3%)
<102 1294 (78.7%) 111 (18.7%)
SBP, mm Hg (Mean ± SE) 119.18 ± 0.61 129.13 ± 0.98 <0.001
DBP, mm Hg (Mean ± SE) 69.46 ± 0.38 73.78 ± 0.72 <0.001
Elevated blood pressure, mm Hg (n, %) <0.001
≥130/85 or medication use 270 (13.0%) 337 (65.3%)
<130/85 or no medication use 1438 (87.0%) 156 (34.7%)
Glucose, mg/dL (Mean ± SE) 92.99 ± 0.38 103.12 ± 0.51 <0.001
Elevated glucose, mg/dL (n, %) <0.001
≥100 or medication use 336 (17.2%) 356 (69.9%)
<100 or no medication use 1372 (82.8%) 137 (30.1%)
HDL-c, mg/dL (Mean ± SE) 57.73 ± 0.65 45.66 ± 1.20 <0.001
Decreased HDL-c Level, mg/dL (n, %) <0.001
<40 for men or <50 for women or
medication use 215 (12.4%) 313 (62.7%)
≥40 for men or ≥50 for women or no
medication use 1493 (87.6%) 180 (37.3%)
Triglycerides, mg/dL (Mean ± SE) 115.83 ± 2.20 208.60 ± 7.06 <0.001
Elevated triglycerides, mg/dL (n, %) <0.001
≥150 307 (18.7%) 335 (69.7%)
<150 1381 (81.3%) 155 (30.3%)











Insulin, µU/mL (Mean ± SE) 7.73 ± 0.22 15.92 ± 0.91 <0.001
HOMA-IR (Mean ± SE) 11.69 ± 0.32 25.06 ± 1.29 <0.001
HOMA-IR, (n, %) <0.001
Quartile 4 271 (14.2%) 245 (53.1%)
Quartiles 1 to 3 1411 (85.8%) 243 (46.9%)
Other Metabolic Characteristics
BMI (Kg/m2, Mean ± SE) 26.86 ± 0.14 33.17 ± 0.38 <0.001
BMI (Kg/m2, n, %) <0.001
Normal weight (<25.0 Kg/m2) 682 (42.8%) 40 (7.1%)
Overweight (25.0–29.9 Kg/m2) 604 (35.5%) 149 (26.9%)
Obese (≥30.0 Kg/m2) 399 (21.7%) 304 (66.1%)
LDL-c, mg/dL (Mean ± SE) 117.33 ± 1.22 120.00 ± 1.81 0.219
Total cholesterol, mg/dL (Mean ± SE) 198.25 ± 1.35 207.75 ± 2.09 <0.001
CRP, mg/dL (Mean ± SE) 0.40 ± 0.03 0.56 ± 0.04 0.119
* Weighted column percentage. Weighted p-values were based on one-way ANOVA tests for continuous variables and Rao–Scott chi-square
tests for categorical variables. BMI, body mass index; CRP = C-reactive protein; DBP, diastolic blood pressure; HDL-c, high-density
lipoprotein cholesterol; HOMA-IR, homeostasis model assessment-estimated insulin resistance; LDL-c, low-density lipoprotein cholesterol;
MET, metabolic equivalent task; MetS, metabolic syndrome; SBP = systolic blood pressure; SE = standard error. Different categories are
indicated by bold subheadings.
3.2. Correlations between Coffee Intake Frequencies and Metabolic Phenotypes and Individual
Metabolic Variables
Among our overall study sample, a total of 1292 (58.7%) participants were coffee
drinkers (Table 2). It was noted that, among the coffee drinkers, 683 (71.8%) individuals
drank ≥ two cups of coffee/day (Table 2). We did not find any significant correlations
between the level of coffee consumption and metabolic phenotypes (Table 2, p = 0.513).
Similarly, no significant difference in overall caffeine intake was observed between the
metabolic phenotypes (Table 2, p = 0.267).









Coffee Consumption (n, %) 0.513
None or ≤1 cup/week 730 (41.3%) 174 (37.0%)
2–6 cups/week 199 (11.4%) 57 (10.6%)
1 cup/day 274 (13.5%) 84 (14.3%)
≥2 cups/day 505 (33.8%) 178 (38.0%)
Caffeine, mg/day (Mean ± SE) 180.91 ± 6.47 193.38 ± 11.54 0.267











<35.3 mg/day 435 (22.3%) 112 (17.8%)
35.5 mg/day–<106.5 mg/day 432 (22.1%) 111 (20.0%)
106.5 mg/day–<219.5 mg/day 426 (25.7%) 136 (28.1%)
≥219.5 mg/day 415 (29.8%) 134 (34.1%)
* Weighted column percentage. Weighted p-values were based on one-way ANOVA tests for continuous variables and Rao–Scott chi-square
tests for categorical variables. SE, standard error. Different categories are indicated by bold subheadings.
As noted in Table 3, several independent metabolic variables were significantly as-
sociated with increased coffee consumption. Consumption of more coffee per day was
significantly associated with reduced BMI (Table 3, p < 0.001). Additionally, increased
coffee intake (one to two cups of coffee/day) was significantly associated with increases
in systolic blood pressure (SBP, p = 0.027), glucose (p = 0.02), LDL-c (p < 0.001), and total
cholesterol (p < 0.001, Table 3). Diastolic blood pressure (DBP), HDL-c, and triglycerides
were unaffected by coffee consumption (Table 3, p = 0.568, p = 0.166 and p = 0.522, respec-
tively). HOMA-IR and CRP were significantly reduced with increased coffee consumption
(Table 3, p < 0.001 and p = 0.021, respectively). However, no significant correlation was
noted between the amount of coffee consumed and the number of metabolic abnormalities
observed (Table 3, p = 0.871).















BMI, Kg/m2 (Mean ± SE) 28.78 ± 0.32 28.45 ± 0.43 27.79 ± 0.47 27.62 ± 0.22 <0.001
SBP, mm Hg (Mean ± SE) 119.96 ± 0.93 121.39 ± 1.35 120.90 ± 1.21 122.83 ± 0.87 0.027
DBP, mm Hg (Mean ± SE) 70.64 ± 0.53 70.24 ± 0.70 69.43 ± 0.89 70.44 ± 0.40 0.568
Glucose, mg/dL (Mean ± SE) 94.43 ± 0.53 95.82 ± 0.73 95.37 ± 0.94 95.61 ± 0.44 0.020
HDL-c, mg/dL (Mean ± SE) 53.42 ± 0.99 55.47 ± 1.24 55.94 ± 1.39 55.63 ± 1.14 0.166
LDL-c, mg/dL (Mean ± SE) 114.31 ± 1.56 116.43 ± 1.84 120.06 ± 2.21 121.59 ± 1.62 <0.001
Total cholesterol, mg/dL
(Mean ± SE) 195.31 ± 1.70 199.36 ± 2.68 202.05 ± 2.65 205.59 ± 1.77 <0.001
Triglyceride, mg/dL (Mean ± SE) 137.70 ± 4.46 135.24 ± 7.85 132.99 ± 5.82 133.79 ± 3.81 0.522
HOMA-IR (Mean ± SE) 16.53 ± 0.99 14.69 ± 0.75 13.96 ± 1.04 12.33 ± 0.41 <0.001
CRP, mg/dL (Mean ± SE) 0.49 ± 0.05 0.47 ± 0.05 0.42 ± 0.04 0.36 ± 0.04 0.021

















0 298 (34.4%) 81 (35.1%) 102 (35.6%) 175 (30.5%)
1 259 (28.1%) 71 (28.0%) 100 (24.8%) 173 (25.3%)
2 173 (18.2%) 47 (17.0%) 72 (17.7%) 157 (21.1%)
3 112 (11.6%) 32 (11.9%) 49 (13.9%) 98 (13.4%)
4 51 (6.3%) 21 (6.6%) 28 (6.8%) 64 (7.6%)
5 11 (1.3%) 4 (1.3%) 7 (1.3%) 16 (2.1%)
Folate, ng/mL (Mean± SE) 12.69 ± 0.39 12.38 ± 0.47 14.20 ± 0.68 14.00 ± 0.49 0.009
Folate, ng/mL 0.009
<8.3 244 (25.5%) 66 (25.0%) 82 (21.0%) 146 (22.9%)
8.3–<11.5 244 (28.1%) 74 (29.8%) 81 (22.5%) 146 (21.8%)
11.5–<16.1 206 (23.3%) 63 (27.5%) 105 (30.8%) 176 (25.9%)
≥16.1 200 (23.0%) 49 (17.7%) 88 (25.8%) 211 (29.5%)
Vitamin B12, pg/mL
(Mean ± SE) 560.65 ± 35.69 487.32 ± 14.25 539.05 ± 19.39 509.55 ± 15.32 0.218
Vitamin B12, pg/mL 0.475
<359.0 203 (25.7%) 73 (29.1%) 83 (25.1%) 179 (28.3%)
359.0–<470.5 218 (25.6%) 68 (29.9%) 77 (22.6%) 177 (26.0%)
470.5–<634.5 227 (24.0%) 55 (22.3%) 96 (26.9%) 169 (24.2%)
≥634.5 236 (24.7%) 55 (18.6%) 97 (25.5%) 147 (21.5%)
* Weighted column percentage. Weighted p-values were based on one-way ANOVA tests for continuous variables and Rao–Scott chi-square
tests for categorical variables. BMI, body mass index; CRP = C-reactive protein; DBP, diastolic blood pressure; HDL-c, high-density
lipoprotein cholesterol; HOMA-IR, homeostasis model assessment-estimated insulin resistance; LDL-c, low-density lipoprotein cholesterol;
MET, metabolic equivalent; MetS, metabolic syndrome; SBP = systolic blood pressure; SE = standard error. Different categories are indicated
by bold subheadings.
It was interesting to note that, when the study population was stratified by BMI
status (Table 4), increased coffee consumption was significantly associated with metabolic
phenotypes among the overweight individuals (Table 3, p = 0.025). After stratifying for
BMI status, overall caffeine intake still was not different between metabolic phenotypes
(Table 3, normal: p = 0.27; overweight: p = 0.96, obese: p = 0.38).
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Table 4. Associations between coffee consumption, caffeine intake, and metabolic phenotypes based on BMI status.
Variable Total(n = 2201)
BMI Status *
























584 (26.6%) 173 (95.4%) 10 (4.6%) 156(91.6%) 18 (8.4%) 134 (57.7%) 88 (42.3%)
Ref Ref Ref
≤1 time/week
320 (13.8%) 111 (95.7%) 6 (4.3%) 78(86.2%)
10
(13.8%) 67 (59.7%) 42 (40.3%)
OR [95% CI] 0.92
[0.27, 3.17]
OR [95% CI] 1.75
[0.67, 4.56]
OR [95% CI] 0.92
[0.52, 1.63]
2–6 times/week
256 (11.2%) 69 (97.2%) 4 (2.8%) 78(87.2%)
16
(12.8%) 50 (57.8%) 37 (42.2%)
OR [95% CI] 0.60
[0.15, 2.44]
OR [95% CI] 1.60
[0.63, 4.08]
OR [95% CI] 0.99
[0.55, 1.81]
1 time/day
358 (13.7%) 108 (95.4%) 7 (4.6%) 102(79.7%)
31
(20.3%) 59 (51.1%) 46 (48.9%)
OR [95% CI] 1.00
[0.26, 3.77]
OR [95% CI] 2.77
[1.24, 6.20]
OR [95% CI] 1.30
[0.73, 2.34]
≥2 times/day
683 (34.6%) 221 (95.7%) 13 (4.3%) 190(77.2%)
74
(22.8%) 89 (49.9%) 91 (50.1%)
OR [95% CI] 0.91
[0.31, 2.72]
OR [95% CI] 3.22
[1.62, 6.39]


















OR [95% CI] for one SD
increase
0.90 [0.50, 1.61]
OR [95% CI] for one
SD increase
1.06 [0.90, 1.25]
OR [95% CI] for one SD
increase
1.11 [0.92, 1.34]
* Weighted column percentage. Weighted p-values were based on one-way ANOVA tests for continuous variables and Rao–Scott chi-square
tests for categorical variables. SE, standard error, Ref, reference group, OR, odds ratio, CI, confidence interval. Different categories are
indicated by bold subheadings.
3.3. Correlations between Micronutrients and Coffee Intake and Metabolic Phenotypes
In the current sample, increased coffee consumption from none/≤1 cup/week to
≥2 cups/day was found to be significantly associated with increased plasma folate levels
(Table 4, p < 0.009), while not significantly associated with plasma vit. B12, either as a
continuous or a categorical variable (Table 3, p = 0.218 and p = 0.475, respectively). Table 5
indicates that the overall total plasma folate was positively associated with MUHP but not
as a categorical variable (p = 0.004 and p = 0.277, respectively). Similarly, lower plasma
level of vit. B12 was significantly associated with an MUHP, both as a continuous and
a categorical variables (p = 0.035 and p = 0.027, respectively). It was interesting to note
that, based on BMI status, increased plasma folate was significantly correlated to MUHP
among the overweight and obese individuals (Table 6, p = 0.001 and p = 0.003, respectively).
Plasma vit. B12 levels were not correlated with metabolic phenotypes based on BMI status
(Table 6, with p-values ranging from 0.44 to 0.57).
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Folate, ng/mL (Mean ± SE) 12.97 ± 0.32 14.65 ± 0.69 0.004
Folate 0.277
<8.3 ng/mL 433 (24.3%) 105 (22.3%)
8.3 ng/ML–<11.5 ng/mL 433 (25.7%) 112 (23.9%)
11.5 ng/mL–<16.1 ng/mL 422 (25.9%) 128 (25.0%)
≥16.1 ng/mL 406 (24.0%) 142 (28.8%)
Vitamin B12, pg/mL (Mean ± SE) 541.64 ± 20.53 494.41 ± 13.40 0.035
Vitamin B12 0.027
<359.0 pg/mL 401 (25.8%) 137 (31.2%)
359.0 pg/Ml–<470.5 pg/mL 415 (25.1%) 125 (28.5%)
470.5 pg/mL–<634.5 pg/mL 431 (25.1%) 116 (21.1%)
≥634.5 pg/mL 430 (24.0%) 105 (19.3%)
* Weighted column percentage. Weighted p-values were based on one-way ANOVA tests for continuous variables and Rao–Scott chi-square
tests for categorical variables. SE, standard error. Different categories are indicated by bold subheadings.
Table 6. Associations between plasma folate and vitamin B12 and metabolic phenotypes, based on BMI status.
Variable Total(n = 2201)
BMI Status *



































OR [95% CI] for one SD
increase
1.27 [0.94, 1.70]
OR [95% CI] for one SD
increase
0.27 [0.10, 2.61]




















OR [95% CI] for one SD
increase
1.04 [0.16, 6.64]
OR [95% CI] for one SD
increase
0.67 [0.19, 2.38]
OR [95% CI] for one SD
increase
1.02 [0.46, 2.25]
* Weighted column percentage. Weighted p-values were based on one-way ANOVA tests for continuous variables and Rao–Scott chi-square
tests for categorical variables. SE, standard error, OR, odds ratio, CI, confidence interval. Different categories are indicated by bold
subheadings.
4. Discussion
4.1. Correlation between Coffee Intake Frequencies and Metabolic Phenotypes
While BMI is the most widely used obesity index, it does not necessarily reflect the
risk of developing metabolic disorders [68–70]. An increasing number of studies have
identified the existence of MHP among overweight and obese individuals as well as MUHP
among normal weight or underweight individuals [71]. There is no universal definition
to categorize these phenotypes and could include a varying number of cardiometabolic
risk factors [10]. Based on the definition of MetS that includes ≥3 cardiometabolic risk
factors, about 22% of our study population demonstrated MUHP, while based on BMI
(≥30 Kg/m2) about 66% demonstrated an MUHP. A study by Winter et al. using the same
NHANES survey data (2003–2004 and 2005–2006) indicated that about 49.8% of the study
population demonstrated MUHP [10]. The differences in the MUHP outcomes are possibly
due to the differences in the classification of MUHP (0 vs. 3 abnormalities) and/or inclusion
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of youth (ages 12 to 18 years) [10]. However, similar to the study by Winter et al., our study
also demonstrates a positive and significant influence of physical activity on MHP [10].
Moderate coffee consumption (2–4 cups/day) has been indicated as a protective fac-
tor for the development of cardiometabolic risk factors [32]. Our results from NHANES
survey data did not indicate any significant correlation between coffee consumption and
overall metabolic phenotypes. However, when the study population was stratified based
on BMI, increased coffee consumption was significantly associated with MUHP among
overweight individuals. Independent studies have indicated that gene–diet interactions
may be associated with lower BMI among genetically predisposed individuals who drank
1–3 cups of coffee/day [27]. Similarly, daily consumption of coffee with bread was associ-
ated with lower visceral adipose tissue and lower prevalence of visceral obesity and MetS
among Japanese population [72]. However, high coffee consumption of ≥3 cups/day was
positively associated with obesity among Korean women [73]. The exact mechanisms of
high coffee consumption with obesity of MUHP remain unclear. However, at a molecular
level, caffeine is known to influence energy balance by increasing energy expenditures and
reducing energy intake [74]. Furthermore, obese individuals consuming coffee containing
high chlorogenic acid for 12 weeks demonstrated reduced accumulation of visceral adipose
tissue, reduced BMI, and reduced waist circumference [75].
4.2. Influence of Coffee Intake on Metabolic Syndrome (MetS) and Its Components
Several studies indicated an improvement of MetS or its components including high
blood pressure with consumption of 2–4 cups of coffee/day ([29,31,33] and references
within). However, we observed that ≥2 cups/day of coffee consumptions was significantly
associated with increased plasma levels of LDL and total cholesterol, as well as systolic
blood pressure (SBP). Our results are similar to those of Kim et al., which indicated that cof-
fee consumption may increase the risk of metabolic syndrome in the Korean population [30].
Conversely, a sex effect was noted in studies by Kim et al., wherein coffee consumption
reduced MetS in Korean women [31]. It is unclear if the adverse effects of coffee on LDL
and total cholesterol noted in our study are related to type of coffee or additives such as
sugar and/or milk/cream. Drinking more than nine cups of coffee per day was positively
associated with increased serum cholesterol among several populations-based studies,
including Japanese men in Hawaii [76,77]. Studies indicate that moderate paper-filtered
coffee consumption for four weeks may increase plasma cholesterol among healthy indi-
viduals [78]. Diterpene cafestol, present in unfiltered coffee, is known to increase serum
cholesterol levels [79,80].
Similar to studies by Wildman et al., we noted that independent cardiometabolic
abnormalities such as elevated HOMA-IR, CRP, elevated triglyceride, and waist circumfer-
ence were significantly associated with MUHP [5]. We further observed that consumption
of ≥2 cups/day of coffee was inversely associated with cardiometabolic abnormalities
including elevated HOMA-IR and CRP but not triglycerides. In our study, it was interesting
to note that regardless of the number of metabolic abnormalities, coffee consumption was
not associated with any metabolic phenotypes.
4.3. Correlation between Micronutrients, Coffee Intake, and Metabolic Phenotypes
Elevated plasma homocysteine is a risk factor for CVD and is influenced by folate and
vitamin B deficiencies including B12 [50,81]. Several studies have linked coffee consump-
tion to increased levels of plasma homocysteine [57,81–85] and inconsistent correlations
with plasma folate or vit. B12 [50,55,81]. In our study population, higher coffee consump-
tion was significantly associated with higher levels of plasma folate (≥16.1 ng/mL). Our
results are in contrast with published studies, which demonstrate that either coffee intake
was not associated with plasma folate [49,81] or significantly lowered plasma folate in
a dose-dependent manner [55]. Similar to another published study, we did not observe
any association of increased coffee consumption with plasma B12 levels [55,81]. Among
the same NHANES population (2003–2004 and 2005–2006), higher plasma folate levels
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were associated with obesity [86]. Similarly, we noted that high plasma folate levels were
associated with MUHP among the overweight and obese population. In contrast, lower
plasma B12 levels were associated MUHP but not with obesity.
The public health relevance of “metabolic phenotypes” is currently unclear, due to
the lack of established definition and criteria as well as its long-term clinical implications.
Studies have indicated that MUHP can develop among 50% of individuals with MHP,
irrespective of their weights and BMI [87,88]. Meta-analysis of epidemiological studies
indicated that intentional weight loss among obese individuals with MUHP lowered all-
cause mortality but had no effect on mortality among the MHP [89]. Current treatment
options for obese individuals are limited and, based on the concept “one size fits all”, may
be counterproductive with “metabolically healthy obese” individuals. Potentially, scarce
and expensive resources can be more effectively used if tailored towards the unhealthy
metabolic profile, regardless of BMI. In view of a rising obesity epidemic, stratifying in-
dividuals based upon their “metabolic phenotypes” could help to improve therapeutic
decision making towards a more individualized treatment plan. Moreover, classification
of metabolic phenotypes and identifying biomarkers of phenotypic transitions is also ex-
pected to detect the metabolic perturbations at an early stage and identify normal weight
individuals at risk, who would otherwise elude detection due to false presumptions of be-
ing “healthy”. A prospective study by Mirmiran et al. indicated that irrespective of the BMI
status, diet can influence the transition of MHP to MUHP among adults [14]. Identifying
possible protective factors such as coffee, folate, or vit. B12 is expected to provide practical
and low-cost dietary intervention targets, specifically for early intervention. Our results
indicate that coffee could be integrated as part of a healthy diet and may have practical
implications to manage chronic diseases or risk factors for metabolic syndrome.
One of the major study limitations is that this is secondary data analysis based on a
national survey, and we are, therefore, limited by what variables are available and how
the information was collected. In addition, this study has limitations possibly arising from
the cross-sectional nature of the data, definition of metabolic phenotypes, and including
only the subpopulation with data on plasma vit. B12 and folate. Our analysis did not take
into consideration the type of coffee or its varieties, coffee preparation methods, ethnicity,
sex, or younger population (ages 12 to 18 years). Regardless, our study suggests the
association of coffee as a possible protective factor with individual components of MetS
and indicates a potentially positive correlation between coffee consumption and MHP
among overweight individuals.
5. Conclusions
Our current study indicates that overall coffee consumption was not correlated with
either MHP or MUHP, but negatively correlated with several metabolic variables. Plasma
folate was positively associated with MUHP, while vit. B12 was inversely associated with
MUHP among our study population.
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